Press Enter to search · Esc to close
A new class of generative models is treating peptide design like a search problem — and the early outputs hint at a faster, more targeted pipeline behind a quarter of all pharma.
Semaglutide and tirzepatide are reshaping body composition for millions of lifters and dieters. A cluster of 2025 reports is starting to map what happens when these drugs collide with surgery, scopes, and scans.
GLP-1s rewrote metabolic medicine, but the syringe is still the weak link. New buccal devices and oral formulations are trying to close the gap — and the data is finally getting interesting.
Patients are shuffling between Ozempic, dulaglutide, and tirzepatide. A small case series and a new biosimilar trial offer the first grounded signals on how this class is fragmenting — and what switching really looks like.
A 2025 meta-analysis of 29 randomized trials suggests GLP-1 receptor agonists trim cardiovascular events in non-diabetic adults with obesity — while parallel reviews push the class into PCOS, perioperative care, and an experimental dual-receptor frontier.
Three recent papers show machine learning moving from hype to workflow in peptide therapeutics — compressing discovery cycles and flagging safety risks earlier. Here's what changes for a field bottlenecked by synthesis and red-cell toxicity.
Semaglutide and tirzepatide rewrote the metabolic playbook. The pipeline behind them is already bifurcating — and what arrives next will look less like one blockbuster shot and more like a stack.
A wave of 2025 research suggests GLP-1 agonists are doing more than shrinking waistlines — nudging lipid panels, reshaping fat tissue, and edging into cardiology and dermatology. The signal is real, but still moderate.
New 2025 data suggests GLP-1 receptor agonists are doing more than shrinking waistlines — with signals across the brain, kidneys, and operating room. Here's what the evidence actually says.
A new wave of peer-reviewed evidence shows GLP-1 drugs reaching further into metabolic medicine—while exposing risks that busy men should know before they fill the prescription.